Rockwell Medical Gains 13.3% Over 12 Weeks with 5.5% Month Surge
Rockwell Medical stock rose 5.5% in four weeks and 13.3% in 12 weeks, reflecting growing investor interest in its kidney disease anemia products. With a beta of 1.7, a Momentum Score of B, Zacks Rank #2 (Buy) and a price-to-sales ratio of 0.53, the shares appear attractively valued.
1. Price Performance
Rockwell Medical stock climbed 5.5% over the past four weeks and 13.3% across 12 weeks, highlighting strong short- and medium-term investor demand for its kidney disease and anemia treatment products.
2. Momentum Score and Analyst Ranking
The shares carry a beta of 1.7, indicating 70% higher volatility than the market, and hold a Momentum Score of B with an upward earnings estimate revision trend securing a Zacks Rank #2 (Buy).
3. Valuation Metrics
Despite rapid price appreciation, RMTI trades at just 0.53 times sales, offering a low price-to-sales ratio that suggests attractive valuation for value investors seeking momentum at a bargain.